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Abstract
Fc γ receptors (FcγR) expressed on the surface of human leukocytes bind clusters of immunoglobulin G
(IgG) to induce a variety of responses. Many therapeutic antibodies and vaccine-elicited antibodies prevent or
treat infectious diseases, cancers and autoimmune disorders by binding FcγRs, thus there is a need to fully
define the variables that impact antibody-induced mechanisms to properly evaluate candidate therapies and
design new intervention strategies. A multitude of factors influence the IgG-FcγR interaction; one well-
described factor is the differential affinity of the six distinct FcγRs for the four human IgG subclasses.
However, there are several other recently described factors that may prove more relevant for disease treatment.
This review covers recent reports of several aspects found at the leukocyte membrane or outside the cell that
contribute to the cell-based response to antibody-coated targets. One major focus is recent reports covering
post-translational modification of the FcγRs, including asparagine-linked glycosylation. This review also
covers the organization of FcγRs at the cell surface, and properties of the immune complex. Recent technical
advances provide high-resolution measurements of these often-overlooked variables in leukocyte function
and immune system activation.
Keywords
antibody, IgG, N-glycosylation, post-translation modification, ADCC—antibody dependent cellular
cytotoxicity, immune complex, ADCP—antibody dependent cellular phagocytosis
Disciplines
Biochemistry, Biophysics, and Structural Biology | Cell and Developmental Biology | Diseases | Immunology
and Infectious Disease
Comments
This article is published as Patel, Kashayp R., Jacob T. Roberts, and Adam W. Barb. "Multiple variables at the
leukocyte cell surface impact Fc γ receptor-dependent mechanisms." Frontiers in Immunology 10 (2019): 223.
doi: 10.3389/fimmu.2019.00223.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
This article is available at Iowa State University Digital Repository: https://lib.dr.iastate.edu/bbmb_ag_pubs/211
REVIEW
published: 14 February 2019
doi: 10.3389/fimmu.2019.00223










Rutgers University, The State






This article was submitted to
Molecular Innate Immunity,
a section of the journal
Frontiers in Immunology
Received: 30 November 2018
Accepted: 25 January 2019
Published: 14 February 2019
Citation:
Patel KR, Roberts JT and Barb AW
(2019) Multiple Variables at the




Multiple Variables at the Leukocyte
Cell Surface Impact Fc γ
Receptor-Dependent Mechanisms
Kashyap R. Patel, Jacob T. Roberts and Adam W. Barb*
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Fc γ receptors (FcγR) expressed on the surface of human leukocytes bind clusters of
immunoglobulin G (IgG) to induce a variety of responses. Many therapeutic antibodies
and vaccine-elicited antibodies prevent or treat infectious diseases, cancers and
autoimmune disorders by binding FcγRs, thus there is a need to fully define the
variables that impact antibody-induced mechanisms to properly evaluate candidate
therapies and design new intervention strategies. A multitude of factors influence the
IgG-FcγR interaction; one well-described factor is the differential affinity of the six distinct
FcγRs for the four human IgG subclasses. However, there are several other recently
described factors that may prove more relevant for disease treatment. This review covers
recent reports of several aspects found at the leukocyte membrane or outside the
cell that contribute to the cell-based response to antibody-coated targets. One major
focus is recent reports covering post-translational modification of the FcγRs, including
asparagine-linked glycosylation. This review also covers the organization of FcγRs at the
cell surface, and properties of the immune complex. Recent technical advances provide
high-resolution measurements of these often-overlooked variables in leukocyte function
and immune system activation.
Keywords: antibody, IgG, N-glycosylation, post-translation modification, ADCC—antibody dependent cellular
cytotoxicity, immune complex, ADCP—antibody dependent cellular phagocytosis
INTRODUCTION: THE IMPORTANCE OF MODULATING THE
Fc-FcγR INTERACTION
Immunoglobulin G (IgG) is the most thoroughly studied and well characterized molecule of
the humoral immune response. IgG activates the immune system through cell-bound Fc γ
Receptors (FcγRs; Figure 1). The IgG fragment antigen-binding (Fab) domains confer specificity
and affinity toward an antigen while the distinct hinge and fragment crystallizable (Fc) domain
of the four IgG subclasses (IgG1-4) provide the structural basis for specificity and affinity to
bind FcγRs (1). The six structurally distinct members of the classical human FcγRs (FcγRI or
CD64, FcγRIIa/CD32a, FcγRIIb/CD32b, FcγRIIc/CD32c, FcγRIIIa/CD16a, and FcγRIIIb/CD16b)
are expressed on leukocytes of both the myeloid and lymphoid lineage (Figure 2). This group
of proteins can be divided into two types: activating receptors (CD64, CD32a, CD32c, CD16a,
and CD16b) that lead to cell activation through immunoreceptor tyrosine-based activation motifs
(ITAM) on cytosolic tails or on co-receptor molecules, and an inhibitory receptor (CD32b) that
signals through immunoreceptor tyrosine-based inhibitory motifs (ITIM) (2–4). Only CD32s
contain ITAM or ITIM domains, and the other receptors must associate with an ITAM-containing
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FIGURE 1 | Multiple variables affect FcγR-mediated immune function. (A) cellular variables influencing FcγR activity that are present before the effector cell engages a
target cell. (B) cellular variables influencing FcγR-mediated activity while the effector cell is engaged with a target cell. (C) molecular variables associated with the
FcγRs, antibody, and antigen.
adaptor protein (FcεRI γ chain or CD3 ζ chain) (3, 5) (Figure 2).
In either situation, the ratio of activating to inhibiting signals
determines the outcome of an immune response (6).
Receptor clustering is essential for FcγR signaling. Circulating
IgG coats an antigen to form an oligomeric complex, positioning
the Fc portions of the IgGmolecules away from the target surface
and exposed to interact with FcγRs. The antibody-coated target
is also referred to as an immune complex. The multiple IgG
molecules of the immune complex provide an opportunity for
multivalent interactions with FcγR-expressing leukocytes and
must compete with non-complexed serum antibodies occupying
the FcγRs that will, in turn, cluster FcγRs on the cell surface
(7, 8). Depending on the receptors engaged, the clustering of
the extracellular domains triggers phosphorylation of tyrosine
in the ITAMs or ITIMs, which subsequently recruits signaling
molecules that promote a cellular response (9). The types of
FcγR-mediated effector cell responses are diverse and include,
but are not limited to, antibody-dependent cellular cytotoxicity
(ADCC), antibody-dependent cellular phagocytosis (ADCP),
release of cytokines and antigen uptake for presentation (10–14).
FcγRs are critical for maintaining immune system homeostasis
as well as preventing pathogenic infections and they play a major
role in inflammatory diseases and autoimmune disorders (9, 13,
15–17). The combination of distinct antagonistic and synergistic
factors contribute to a considerable functional diversity within
this group of antibody receptors. Here we will discuss multiple
factors which influence the antibody:FcγR interaction and
modify the immune response (Figure 1).
RECEPTOR PRESENTATION AT THE CELL
SURFACE
FcγRs are predominately expressed on cells originating from
hematopoietic progenitor stem cells including dendritic cells,
neutrophils, basophils, eosinophils, macrophages, monocytes,
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FIGURE 2 | Structures and properties of the human Fc γ receptors. Five receptors are expressed in the majority of the population with CD32c expressed only in a
small subset. The ribbon diagrams show the structures of the extracellular antibody-binding domains as determined by x-ray crystallography; overlayed black or white
circles indicate the sites of N-glycosylation.
mast cells, NK cells, B cells, a subset of T cells, and platelets as
well as non-hematopoietic cell types such as syncytiotrophoblasts
at various levels (18–20). FcγR expression varies depending
on cell lineage; not surprisingly gene copy number is also
implicated in disease. These factors can greatly influence the
dynamic ability of the immune system to respond to the diverse
repertoire of foreign invaders. Thus, variable surface expression
by different immune cell types influences how the immune
system responds to a foreign invader. This section will cover
the cellular expression of FcγRs and immune modulation of
expression through downregulation and induction.
Five activating FcγRs are expressed in humans (Figure 2). The
highest affinity, CD64, is expressed on monocytes, dendritic cells
and macrophages (11), mast cells (21), and neutrophils following
IFN-γ exposure (22, 23). The low affinity CD32a is expressed on
mast cells, neutrophils, macrophages, eosinophils, and platelets
(24). CD32c is expressed by 7–15% of individuals on NK cells and
B cells and results from a gene mutation (4). The high/moderate
affinity CD16a is expressed predominantly on NK cells, a subset
of monocytes, mast cells, basophils, macrophages and is inducible
in CD4+ T-cells (25, 26). The low/moderate affinity CD16b
is found only in humans and expressed predominantly on
neutrophils (27), a subset of basophils (28) and has inducible
expression on eosinophils (29, 30). CD32b is the sole inhibitory
receptor and is expressed on basophils, B cells, macrophages,
dendritic cells, a subset of monocytes and neutrophils (24).
Interestingly, CD32b is also expressed in non-hematopoeitic
cells, including the endothelium of various organs (31).
Variability in Receptor Amount
Gene duplications in individuals lead to copy number variation
(CNV) of some FcγRs in the population. Surprisingly, only
CD16a, CD16b, and CD32c of the FcγRs exhibited CNV in
a sample population of 600 subjects (32). CNVs have been
correlated to autoimmune disorders as well as variations in
surface expression levels. CNV of CD16b is correlated to surface
expression on neutrophils and implicated in SLE susceptibility
(33, 34), as well as other autoimmune disorders (35, 36).
Furthermore, CD16a CNV appears to be functionally significant
since increased surface expression positively correlated with
increasing CD16a gene number (ranging from one to three
copies) (32, 35). A CD16a indel has been shown to increase
surface expression as well (37).
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FcγR amount at the cell surface varies by cell type and receptor
identity (Figure 2). On neutrophils, there are an estimated
100,000–300,000 surface exposed CD16b molecules and 10,000–
40,000 CD32a molecules (38, 39). The predominant monocyte
subtype at roughly 80% of the pool, “classical” monocytes, does
not express CD16a. “Non-classical” monocytes express CD16a
at a level of roughly 10,000 CD16a molecules per cell but
upon differentiation into macrophages express 40,000 CD16a
molecules per cell while CD32 remained the same at ∼10,000
molecules per cell (40). Another study found macrophages
express 5–10 fold higher CD64, CD32a, and CD32b while
CD16a expression was comparable to non-classical monocytes.
M2c macrophages expressed overall higher levels of FcγRs
than M1 macrophages with the following order of expression:
CD32a, CD32b > CD64 > CD16a (41). A high number of
CD16a molecules are expressed on CD16+ NK cells (100,000-
250,000) (42).
Expression levels also vary based on the cell status. Following
activation, innate immune cells can induce expression of
FcγRs (23, 25, 29, 30, 35). There is also evidence of receptor
downregulation upon activation. Downregulation mechanisms
include both decreases in expression as well as shedding FcγR
from the cell surface following metalloproteinase cleavage.
CD32a is shed from Langerhans cells and also expressed as a
soluble form (43). CD32b is shed upon activation of B-cells (44).
CD16a and CD16b are likewise shed upon activation of NK cells
and neutrophils at a known cleavage site by the metalloprotease
ADAM17 (45–48). Intriguingly, sCD16b is relatively abundant in
serum (∼5 nM) (49) and levels vary based on the immune state of
the individual (50). Surprisingly, CD64 is the only human FcγR
in which a soluble, serum-borne form has not been reported.
This may be explained by the presence of a third extracellular
CD64 domain in place of the cleavage site found in CD32s and
CD16s (Figure 2).
Soluble FcγR forms modulate immune responses. Soluble
CD16b binds myeloid cells, NK cells, subsets of T cells, B
cells, and monocytes through complement receptor 3 (CR3 or
Mac-1 or αM β2, comprised of CD11b/CD18) and complement
receptor 4 (CR4 or αx β2, comprised of CD11c/CD18). These
interactions cause the release of IL6 and IL8 by monocytes and
indicate a potential role for soluble CD16b in inflammation
(51). Shedding of CD16a from NK cells allows disengagement
of the immune synapse from the target cell and the subsequent
ability to kill again. One study demonstrated that repeated
engagement by CD16a depleted perforin, however, shedding
of CD16a allowed perforin replenishment upon subsequent
activation by another activating receptor, Natural killer group
2 member D (NKG2D), which recognizes ligands not normally
expressed on healthy tissue (52). Thus, it appears that the act
of shedding of CD16 can allow disengagement of the foreign
particle which would be crucial for the immune cell’s survival
and preservation of potential future cytolytic activity. Though
shed receptors are proinflammatory and recruit immune cells
as discussed above, a complete picture of the mechanisms of
regulating surface expression upon immune activation is not
currently available.
Receptor Clustering at the Membrane Is
Required for Effector Function
The correct presentation of FcγRs on the cell membrane is
essential for proper immune cell function. ADCC can destroy
virally infected cells and cancer cells, and is thus a target for
monoclonal antibody (mAb) therapies (53). ADCP is also an
important mechanism in mAb therapy targeting malignant cells
(14). ADCC and ADCP are dependent on the ability of low to
moderate affinity FcγRs to cluster on fluid plasma membranes
for activation to occur (54) (Figure 1). Equally important is the
regulation of these receptors when no activation signal is present.
Proper activation of FcγRs following Fc engagement by
macrophages requires clustering of FcγRs and the displacement
of inhibitory receptors. In one study utilizing murine RAW
264.7 cells, segregation of CD45, a phosphatase responsible for
dephosphorylating ITAMs, is dependent on antigen distance
from the target membrane (55) (Figure 1). It appears that if
the antibody is >10 nm from the target surface, there is a
substantially impaired ADCP response. This phenomenon is due
to the location of the epitope; epitopes closer to the surface
exclude the inhibitory CD45 molecule (which stands∼22 nm tall
vs. FcγR-IgG complex = 11.5 nm) from the immune synapse.
Interestingly, a follow-up study that focused on FDA-approved
mAbs found the targets were small surface proteins (<10 nm
in height) suggesting there may be a requirement for mAb
epitopes to be located close to the surface for therapeutic efficacy.
CD45 was also excluded from the immune synapse in activated
human T cells (56). Another study concerning inhibitory module
segregation on humanmacrophages demonstrates CD64, but not
CD32a, and inhibitory signal regulating protein α (SIRPα), in
conjunction with CD47 (a receptor that inhibits macrophage
phagocytosis), are clustered on quiescent cells but upon
activation segregate in a process regulated by spleen tyrosine
kinase (SYK)-dependent actin cytoskeleton reorganization (57).
Recently, FcγR diffusion has been shown to be inhibited by
the CD44 transmembrane protein which is immobilized by
linearized actin filaments via ezrin/radixen/moesin (ERM) and
binds hyaluronan in the glycocalyx (58). This study used
primary human macrophages as well as murine cell lines
and murine models, utilizing single particle tracking found
CD44 and hyaluronan decreased the diffusion rate of FcγRs,
while also sterically blocking the binding of FcγRs to immune
complexes (Figure 1).
Receptor clustering overwhelms constitutive inhibition
as described previously, allowing phosphorylation of the
ITAM. ITAMs are phosphorylated via SYK, Src family kinase
(SFKs) or ζ-chain-associated protein kinase 70 (ZAP-70) for
downstream activation of phosphoinositide-3-kinase (PI3K),
NF-κB, extracellular signal regulated kinase (ERK), phosphatidyl
inositol 4-phosphate 5-kinase γ (PIP5Kγ), GTPases and other
SRC-family kinases (53, 54, 59, 60). Along with FcγR clustering,
actin polymerization and depolymerization is equally important
for phagocytosis in RAW 264.7 macrophages by creating
lammellipodium/pseudopods. These protrusions are controlled
by Rac GTPase and lipid composition (54, 59) (Figure 1).
Clustering has also been observed on the plasma membrane
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of murine derived macrophages using total internal reflection
microscopy (TIRF) of a lipid bilayer supporting IgG (61). The
FcγR microcluster appears on the macrophage pseudopod edge
and is subsequently transported to a synapse-like structure
thereby recruiting SYK and production of PtdIns(3–5)P3
coordinated with lamellar actin polymerization. Another study
on quiescent human macrophages found lateral diffusion
of FcγRs is regulated by tonic activity of SYK causing actin
cytoskeleton organization to increase the likelihood of FcγRs to
be pre-clustered upon finding a pathogen (62).This study further
described differential FcγR mobility upon activation. FcγRs at
the periphery of the actin-rich pseudopod weremoremobile than
those already immobilized by binding of IgG-rich regions. The
authors explained that this mobility difference is controlled by
SYK-mediated regulation of the actin-cytoskeleton which would
increase the likelihood of FcγRs to engage more IgG molecules at
the leading edge of the lamellipodium/pseudopod and not waste
time diffusing into already IgG-dependent, FcγR-immobilized,
actin-rich rich regions of plasma membrane. Mobility of FcγRs
was described earlier to be decreased at the trailing end of
polarized macrophages by CD44 that was bound to linear actin
and connected to hyaluronan (58). It was also found in this
study that on the leading edge of polarized macrophages, the
side that encounters opsonized material, Arp2/3-driven actin
branching predominates, initiated by phosphotidlyinosotide
(3–5)-trisphosphate production, and increased FcγR mobility
allowing for more efficient clustering at the immune synapse.
When Arp2/3-driven actin branching predominates, it
was found CD44 is more mobile allowing greater FcγR
mobility (Figure 1).
In the human NK92 cell line, transduced to express CD16a,
a study showed β2 integrins mediate the dynamics of FcγR
receptor microclusters in a protein-tyrosine kinase 2 (Pyk2)-
dependent manner, controlling the rate of target cell destruction
by ADCC (63). β2 integrins bind ICAM-1 on the target cell
allowing adhesion and signal transduction through Pyk2 for
actin remodeling and the subsequent enhancement of FcγR
mobility. Furthermore, sites of granule release are surrounded
by clusters of CD16a and release points are devoid of actin.
Human NK cell lytic granules also converge at the surface in a
dynein and integrin-signal dependent manner which aids spatial
targeting of the weaponized molecules to limit off-target damage
(64). Surprisingly, CD16a is essential for ADCC of human
CD16+ monocytes and upon CD16a engagement, β2 integrins
are activated along with TNFα secretion thereby indicating that
non-classical monocytes (CD16+) are the sole monocyte class
capable of ADCC (65).
During the early stages of phagocytosis by RAW 264.7 cells,
direct contact between FcγRs and IgG is increased by greater
IgG density on particles, and increased IgG density results in
an increased level of early signals. However, late stage signals
are “all or nothing,” not concentration dependent, and regulated
by PI3K concentration in the phagocytic membranes (66). In
this study, low IgG density decreased the amount of opsonized
particles but not the rate of phagosome formation and low IgG
density particles that did result in phagocytosis recruited the
same amounts of late stage signaling molecules (PIP3, Protein
kinase C ε type, p85 subunit) and actin. Overall it appears
that FcγRs control the initial binding process essential for
scanning the foreign particle and initial activation by binding
IgG and later stages of commitment to destruction of the
particle are controlled by both IgG density and membrane
lipid composition.
On murine and human macrophages, receptor clustering
upon activation is consistent with a change in the heterogeneity
of the membrane lipid composition to a highly ordered
phagosomal membrane that is heavily enriched in sphingolipids
and ceramide but lacking cholesterol (67) (Figure 1). The authors
state that lipid remodeling mediates F-actin remodeling and
the biophysical characteristics of the phagosomal membrane are
essential for phagocytosis. On human B cells, a polymorphism
of the inhibitory receptor CD32b (Ile232Thr) located in the
middle of the transmembrane domain, is described to decrease
inhibitory function (68). This mutation was shown to result
in aberrant localization to a sphingolipid and cholesterol rich
region in contrast to the Ile232 wild-type. Aberrant localization
is not surprising considering the introduction of a polar residue
into the transmembrane domain (69). Furthermore, the ability
of CD32b to inhibit B cell receptor (BCR)-mediated PIP3
production, AKT, phospholipase C-γ-2 (PLCγ2) activation and
calciummobilization was impaired in cells expressing the CD32b
Thr232 allotype as compared to Ile232. The authors indicate the
FcγR locus was associated with SLE and this polymorphism may
promote disease. Thus, it appears lipid composition is important
for FcγR-mediated mechanisms.
The unique construction of CD16b indicates the potential for
a different activation mechanism for neutrophils. Neutrophils
predominantly express CD16b with 10-fold less CD32a. CD32a
signal transduction is well described and thought to be the
canonical FcγR signal transduction via phosphorylation of
ITAMs and subsequent SYK recruitment (70). However, CD16b
contains a GPI anchor and does not have a polypeptide
transmembrane domain nor is it known to associate with
a signaling coreceptor, therefore, it is unclear how CD16b
promotes signaling in neutrophils (Figure 2). CD16b plays a
role in the initial binding of immune complexes in concert
with β2 integrins (71). Currently there are conflicting studies
suggesting that CD16b can transduce a signal on its own
(70, 72, 73), or it transduces a signal by acting with CD32a
(74). A recent study found CD16b cross-linking increased IL-
10 and TNFα expression, phosphorylated SHP-2 in a lipid-raft
mediated manner and inhibited apoptosis in neutrophils. Lipid
composition certainly may be an important part of CD16b signal
transduction inmechanisms similar to those discussed previously
for macrophage phagocytosis and CD32b on B-cells, however the
role of lipids in neutrophil activation is not understood (75–81).
Interestingly proteinase 3 (PR3), CD16b, cytochrome b558, and
NADPH oxidase co-immunoprecipitate on lipid rafts and PR3
and CD16b colocalize in confocal imaging suggesting these may
interact in a lipid raft (75). Other findings suggest CD16b signals
in conjunction with CR3 via lectin-like interactions (82), leading
to neutrophil respiratory bursts (72). The function of GPI-linked
CD16b remains undefined despite the high abundance of CD16b
in the body and critical roles in mAb therapies (83).
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FIGURE 3 | N-glycans are processed in the ER and Golgi to produce three major classes: minimally processed oligomannose-type N-glycans, fully processed
complex-type N-glycans, and hybrid-type N-glycans with an intermediate level of processing.
The Type of FcγR Membrane Anchor
Impacts Activation
There are clear differences between the signaling and antibody-
binding affinity of soluble and membrane-anchored FcγR forms.
However, less is known about the effects of the specific FcγR
membrane anchors on affinity and cell activation. All FcγRs
are localized to the membrane by a transmembrane polypeptide
moiety or a glycosylphosphatidylinositol (GPI) moiety (CD16b
only) (Figure 2). A micropipette adhesion assay demonstrated
CD16a attached tomicrospheres via a GPI anchor bound roughly
5-fold tighter to IgG1-coated red blood cells (RBCs) than CD16a
tethered by a transmembrane domain (84, 85). Interestingly, it
also appears IgG1-coated spheres treated with phosphoinositide
phospholipase C (PIPLC) to remove the diacylglycerol moiety
bound to GPI-linked CD16a with 12-fold less affinity. These
authors observed a 60-fold decrease when the GPI-anchor was
completely removed. A CD16b-GPI construct showed 2-fold
decrease of affinity upon PIPLC treatment and an 11-fold
decrease following removal of the GPI-anchor. The authors
hypothesized that enhancement of binding affinity associated
with the GPI anchor may be due to an allosteric effect on CD16,
changing the structure to bind IgG more effectively; such an
allosteric mechanism was observed with other GPI-anchored
proteins (80). Further studies will be required to fully elucidate
how the GPI-anchor affects CD16b and how specific aspects of
the membrane anchor confers distinct properties in vivo.
POST-TRANSLATIONAL MODIFICATION
OF THE ANTIBODY AND RECEPTOR
Asparagine-linked (N-) glycosylation is one of the most
common protein modifications performed by the eukaryotic
cell and is a substantial modification of all FcγRs [Figure 2;
for a thorough review of N-glycan processing, see (86)].It is
important to note, however, the resulting glycans processed in
the ER and Golgi can be grouped into three distinct forms:
(1) minimally-processed oligomannose type N-glycans, (2)
intermediate processed hybrid-type N-glycans with processing
on one of the two core mannose branches, and (3) highly-
processed complex-type N-glycans with extensively modified
branches (Figure 3).
Several variables introduce a significant degree of
heterogeneity into the N-glycan present at any single site
on a glycoprotein, ranging from substrate availability, protein
anchor type, to accessibility of N-glycan site, potentially creating
a vast diversity of protein forms and functions (87–90). This
heterogeneity also renders glycoproteins challenging targets for
in vitro studies to characterize structure. Minimally-processed
hybrid and oligomannose type N-glycans are not expected at
the cell surface because these forms harbor terminal mannose
residues that may bind to the mannose receptor and elicit an
immune response (91, 92). Though many previous glycomics
studies report high levels of oligomannose N-glycans recovered
from primary cells, the abundance of these under-processed
forms is likely due to cell lysis and recovery of unprocessed
glycans from the ER. If under-processed forms are present on
the cell surface, these must be protected from binding to the
mannose receptor. Therefore, highly processed complex-type
N-glycans are expected as the predominant species at the
cell surface.
The functional impact of N-glycosylation at the conserved
asparagine 297 residues in IgG1 is well established. IgG1
glycosylation at Asn-297 is essential for the IgG-FcγR interaction
(93). The N-glycosylation profile of serum IgG changes
due to multiple factors, including age, gender, infection,
pregnancy, and disease (94–97). The variation in IgG1 Fc
glycoforms is known to change antibody affinity toward the
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FcγRs (98), and this fact has also been leveraged to develop
glycoengineered mAbs and anti-inflammatory glycoforms of
intravenous immunoglobulin (IVIG) (99, 100). The wealth
of knowledge regarding IgG glycoforms is due in large
part to protein abundance and ease of obtaining samples.
However, little is known about the glycosylation of FcγRs on
immune cells.
FcγRs are heavily glycosylated molecules, containing two to
seven N-glycans (Figure 2). The extent of FcγR modification
was evident as early as 1988 as certain FcγRs from native tissue
migrated much slower in SDS-PAGE gels than expected based
on the polypeptide mass alone. Furthermore, the migration rate
increased after treatment to specifically remove N-glycans (101,
102). There is a prominent gap in knowledge about the impact of
FcγR N-glycosylation on immune function largely due to limited
studies of the native FcγRs purified from primary leukocytes.
However, it is known that CD16a expressed by NK cells
had a distinct N-glycosylation profile when compared CD16a
expressed by cultured monocytes, though this determination
was made using lectin binding (103) and surface CD16a on the
NK cell and monocyte displayed differential antibody-binding
affinity that was attributed to differences in cell-specific CD16a
N-glycosylation (104).
Even though native glycoforms of all FcγRs are not known,
the effect of N-glycosylation on binding affinity has been well
characterized in vitro using protein expressed with mammalian
cells. Aglycosylated, recombinant, soluble (s)FcγRs bind IgG1
Fc at different affinities than glycosylated forms, thus the IgG-
FcγR interaction is sensitive to receptor N-glycosylation (105–
107). Recent studies reported substantial differences in affinity
for sFcγRs expressed in recombinant systems (106, 108–110),
N-glycosylation profiles of NK cell CD16a and soluble CD16b
from serum revealed surprising heterogeneity and substantial
differences from recombinantly-expressed protein (109, 111).
Specific CD16a Glycoforms Bind Antibody
With High Affinity Comparable to CD64
The analysis of N-glycan composition from FcγRs provides
a characteristic profile of a protein (112). Glycomics analysis
of CD16a on circulating NK cells from three healthy donors
revealed a surprising abundance of under-processed forms
(∼45% hybrid and oligomannose-type N-glycans). CD16a is
N-glycosylated at five sites (Figure 2). The remainder of
the N-glycans were primarily complex type, biantennary N-
glycan structures with a high degree of sialylation (78%) and
fucosylation (89%) (109). The under-processed forms do not
likely originate from unprocessed CD16a in the ER because all
of the observed hybrid forms were sialylated, a modification
that occurs in the late Golgi compartments (113) (Figure 3).
Moreover, the presence of oligomannose type N-glycans on
CD16a from almost all recombinant sources suggests that
restricted processing is a conserved feature (108–110). N-glycans
at Asn38 and Asn74 were not observed using this glycomics
approach to study NK cell CD16a; perhaps these large glycans
ionize too poorly to be observed in a derivatized form, but robust
ionization of the peptide provides measurable signals for CD16b
N38 and N74 glycopeptides (111).
Recombinant expression has thus far failed to generate CD16
with glycan profiles matching those measured for CD16a or
CD16b from primary cells. CD16a is the most heavily studied
FcγR due to its role in ADCC and the associated therapeutic
applications. Glycomics characterization of soluble extracellular
domain of CD16a (sCD16a) from HEK293, NS0, and CHO cell
lines showed stark differences when compared to CD16a from
NK cells, including a high abundance (over 90% compared to
55% in NK cells) of biantennary and triantennary complex type
N-glycans with low levels of sialylation (108–110). Moreover,
each recombinant system has the potential to synthesize unique
N-glycan structures that are not commonly found on native
human proteins, such as LacDiNAc (GlcNAc-GalNAc) from
HEK293 cells, α-Gal epitopes (αGal-βGal-βGlcNAc), terminal N-
acetylglycolylneuraminic acid in NS0 cells and only α-2,3 linked
sialic acids in CHO cells (106, 114). These terminal modifications
can potentially alter the binding affinity to IgG in an unexpected
and undesirable manner.
Differences between native and recombinant CD16a
processing render studies of binding affinity using recombinant
material suboptimal, however, these materials still represent
the best option for many in vitro studies. Furthermore, binding
affinitymeasurements have utilized the soluble extracellular FcγR
domains due to challenges associated with extracting full-length
material from the membrane. Tethering CD16a to the membrane
changes the N-glycosylation, likely due to differential localization
within the Golgi (88, 109). Unfortunately, the N-glycosylation
profile of full-length CD16a (frCD16a) expressed with HEK293
cells revealed an N-glycan profile unlike that found on NK cells
(109). N-glycans from frCD16a showed less under-processed
oligomannose and hybrid types (27% in frCD16a and 45% in
NK cell CD16a) and the complex-type N-glycans were highly
branched. Thus, cell-type specific glycosylation accounts for
the dissimilar N-glycan profile on CD16a from primary and
recombinant sources and impacts binding affinity measurement,
as discussed below.
Recombinant FcγRs are valuable to characterize the role of
N-glycosylation on IgG binding affinity, despite clear differences
in N-glycan processing when compared to endogenous material.
One recent study reported a 40-fold increase in affinity toward
afucosylated IgG1-Fc (G0 form) when complex type N-glycans
on CD16a were replaced with Man5 N-glycans (110). This
gain revealed that CD16a can bind with an affinity comparable
to CD64, the “high affinity FcγR.” A comparable study
demonstrated that higher amounts of larger sialylated complex
type N-glycans on CD16a expressed in CHO cells correlated with
lower affinity for Rituximab (108).
Of five CD16a N-glycans, only two appear essential for
high affinity interactions. Mutating the protein to eliminate N-
glycan addition with N45Q and N162Q substitutions reduced
the affinity for IgG1-Fc (109, 115–117). However, the reported
influence of N-glycan composition was primarily driven by the
N-glycan at N162: only the N162Q mutation abolished the
affinity gain due to Man5 N-glycans on CD16a (110). These
observations are in agreement with the fact that glycans at N45
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and N162 form interactions with the CD16a polypeptide and
influence protein structure (118) and glycans at these two sites
showed the greatest restriction in N-glycan processing using the
HEK293 and CHO systems (119). Thus, cell-type specific CD16a
N-glycosylation patterns influence affinity for IgG1 and a range
of potential affinities are accessible purely through modifying
N-glycan processing.
N-glycosylation of CD16b
CD16b is a highly similar paralogue of CD16a and only found in
humans (97% sequence homology of the extracellular antibody-
binding domain). However, two common CD16b alleles encode
either four (NA1) or six (NA2) N-glycosylation sites (120,
121) (Figure 2). Considerable site-specific diversity in N-glycan
structures was present on sCD16b obtained from 2l of pooled
human serum (111). Serum sCD16b is generated by ADAM17
cleavage of cell surface CD16b upon neutrophil activation (48).
Thus, sCD16b were likely membrane bound when the N-glycans
were being processed. The N-glycans at each site had unique
profiles ranging from smaller oligomannose type N-glycans at
N45 to large complex type N-glycans with extensive elongation,
sialylation, and fucosylation at N38 and N74, unlike sCD16b
expressed in recombinant systems (106, 114, 122). Additionally,
allele specific (NA1 and NA2) N-glycosylation profile at N162
and N45 of donor matched serum and neutrophil CD16b
confirmed the observations of CD16b from pooled serum,
revealing moderate variability in the abundance of the most
prominent glycoforms (123). The profile of sCD16b from serum
was distinct from CD16a expressed by NK cells that displayed
a greater level of under-processed N-glycans (109, 111). The
presence of oligomannose type N-glycans only at N45 strongly
suggests under-processing of N-glycan is restricted to a single site
on the protein with as many as six N-glycosylation sites (111).
The stark differences in the glycosylation profile of sCD16b
from serum compared to recombinant sCD16b further
emphasized the importance of cell type specific N-glycosylation.
Glycomics analysis of CD16b from HEK293, NS0 and BHK
revealed mainly multiantennary complex type N-glycans with a
high degree of sialylation and fucosylation (106, 114, 122). The
N-glycosylation profile of recombinant sCD16a and sCD16b
are comparable as most of the N-glycosylation sites are shared
(124). There was a minimal difference (2-fold increase) in
affinity when sCD16b-Man5 binding to IgG1-Fc (G0F form)
was compared to sCD16b with complex-type N-glycans (110).
This was surprising considering that the extracellular antibody
binding domains of CD16a and CD16b (NA2) differ at only four
amino acid residues. Moreover, both CD16s are functionally
distinct because CD16a-complex type has a 15-fold greater
affinity for IgG-Fc than CD16b-complex type (110). The affinity
and sensitivity to glycan composition for CD16b was improved
to that of CD16a by mutating a single residue, Asp129, to Gly
based on the CD16a sequence (124). The authors demonstrate
with x-ray crystallography and molecular dynamics simulations
that Asp129 buckles the CD16b backbone upon binding IgG1
Fc. Thus, buckling shifts a nearby residue, Arg155, which makes
a different contact with the N162-glycan that is not observed
in CD16a.
N-glycosylation of CD32
The N-glycosylation profiles of sCD32a and sCD32b expressed
with recombinant systems were highly comparable (106, 108,
114). There are two to three N-glycosylation sites on CD32:
CD32a (3), CD32b (2), and CD32c (2; 32b and 32c have
identical extracellular domains) (Figure 2). Glycomics analysis
of CD32a and CD32b expressed in HEK293, NS0, and CHO
displayed predominantly biantennary and triantennary complex
type N-glycan structures with a low degree of sialylation and
varying levels of fucose (106, 108, 110, 114). Binding affinity
between sCD32a and sCD32b was comparable and neither
appeared sensitive to N-glycan composition as sCD32(a or b)-
Man5 and sCD32(a or b)-complex type bound IgG1 Fc with
similar affinities (106, 110). CD32a polymorphisms (R131 or
H131) cause differences in binding to IgG subtypes, potentially
changing the sensitivity of immune complexes to phagocytosis
by neutrophils and monocytes (121, 125). However, N-glycan
analysis on the receptor expressed in CHO cells showed no
substantial difference in glycosylation pattern between the
two CD32a allotypes (108). The site-specific N-glycosylation
profile and native N-glycosylation profile for any CD32 is not
currently available.
N-glycosylation of CD64 Also Impacts
Binding Affinity
The high affinity FcγR, CD64, is distinct from other FcγRs
because it contains an additional extracellular domain (126).
Moreover, CD64 can potentially receive N-glycosylation
modification at seven sites in its extracellular domain (Figure 2).
A comparative glycomics analysis of the sCD64 expressed in
HEK293, NS0, and CHO cell lines showed biantennary and
multi-antennary complex type N-glycans with varying degrees
of sialylation and fucosylation as the most abundant glycoforms
(106, 108, 114). A distinct feature which was conserved across
sCD64 expressed in all three cell lines was the higher abundance
of oligomannose structures when compared to recombinant
CD16 or CD32. It was speculated that the presence of Man5
forms (the most abundant oligomannose N-glycan in these
cell types) conferred a stabilizing effect toward IgG1 binding
since the higher abundance of Man5 forms (14.4% in NS0
and 5.2% in CHO) correlated with an increase in binding
affinity to Rituximab (108). According to the authors, the
increased affinity was due to the lack of core fucose on the
Man5 structure which can potentially prevent steric hindrance
effects similar to that observed in fucosylated N-glycan on
IgG1 (115, 127). The authors also observed that the presence
of large sialylated complex type N-glycans on CD64 correlated
with reduced binding affinity for Rituximab, indicating that
these glycans destabilized the interaction (108). Even though
N-glycan composition on CD64 can affect IgG1 affinity, the
N-glycosylation profile of native CD64 and the composition of
N-glycans at each site remains unknown.
N-glycosylation processing depends on the amino acid
sequence and secondary structures which affect the exposure
of substrate monosaccharide residues to the glycan processing
enzymes (Figure 3). Presence of both the under-processed and
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highly-processed (tetraantennary sialylated) N-glycan structures
on NK cell CD16a and recombinant sCD64 suggests site-specific
glycan modification. Oligomannose structures at specific sites
on sCD16a have been implicated in modulating IgG affinity;
similarly, specific sites on CD64 can be involved in modulating
CD64-IgG1 affinity (108, 110). Thus, a thorough analysis
of site-specific N-glycosylation analysis of recombinant and
endogenous FcγRs from all expressing tissues is required to fully
elucidate the role of N-glycosylation pattern at specific sites in
affinity modulation.
HOW MULTIVALENCY IMPACTS IgG-FcγR
INTERACTIONS
Investigating factors that contribute to the monovalent affinity
of IgG-FcγRs interaction revealed clear differences in the affinity
of antibody subclasses for certain receptors, however, multivalent
avidity likely determines the in vivo immunological response
initiated by these interactions. High IgG concentrations in
the serum of ∼10 mg/ml provide monomeric antibody to
the receptors at a concentration of ∼67µM, vastly exceeding
the KD of IgG1 for all human receptors (7). Thus, surface-
borne FcγRs are occupied on cells circulating in the peripheral
compartment and multivalent interactions must compete with
monomeric IgG to cluster receptors (7, 8). Receptor cross-
linking and clustering on the effector cell surface is essential
for signal transduction through FcγRs, thus multivalent immune
complexes or opsonized targets are the functionally appropriate
ligands for the receptors (Figure 1) (54, 128). Distinct FcγRs are
engaged depending on the responding cell type, the IgG subclass,
the antibody concentration on the opsonized target, and the
size of immune complex (Figures 1, 2) (129, 130). Furthermore,
the differential binding of immune complexes has therapeutic
as well as pathogenic properties, especially during infection and
autoimmune disease but not all aspects are well-defined (9, 15).
Therefore, defining the critical factors associated with immune
complex recognition is required to fully understand the antibody-
mediated immune response.
Immune Complex Size Determines Effector
Function
The importance of interactions between multiple monovalent
ligands and multiple receptors is well known, however, the
study of multivalent interactions remains challenging. Early
attempts to generate multivalent immune complexes through
heat aggregation of IgG produced aggregates with varied valency,
immunogenicity and ill-defined sizes (131, 132). Technological
advances in recent years produced immune complexes of defined
size and valency which accurately represent those generated
in vivo (130). Functional interrogation using defined immune
complex revealed that immune complex size contributes to
interactions with FcγRs.
Immune Complex Size Affects Binding
The concentration of antigen-specific antibody in the serum
and likewise immune complex size is expected to change
during an immune response, and size-associated changes in the
immune response are well described (130, 133). Nimmerjahn
and coworkers used well-defined immune complexes formed
by all four IgG subclasses binding to FcγRs expressed on a
CHO cell surface to systematically determine that there was
a clear size-dependent gain in binding by IgG2 and IgG4
immune complexes and the size of an immune complex can
overcome IgG glycan truncation, a modification that destroys
themonovalent interaction (134).Moreover, the binding patterns
were comparable to experiments using primary leukocytes that
increased cytokine secretion in response to larger immune
complexes. These data led to amathematical model that describes
effects of valency and IgG subclass on in vivo function (135).
The differential binding due to a change in the size of immune
complex can potentially lead to substantial changes in cell
signaling and recent technical advances provide a means to
quantitate signaling with cell-based assays (136).
Role of Immune Complex Size in Autoimmune
Disorders
The formation of immune complexes with soluble self-antigen
is implicated in the pathophysiology of several autoimmune
diseases (137). IVIG is a frequent treatment for a variety of
autoimmune disorders, but the exact mechanism of action is
not known (138). Even though there is a well-documented
role of CD32b in decreasing an immune response triggered by
autoantibody immune complexes in murine model of immune
thrombocytopenia (ITP) (139), a recent study demonstrated that
engaging the inhibitory CD32b alone is not responsible for the
decrease in phagocytosis of RBC opsonized by autoantibody
in human ITP patients. Instead, the direct engagement of
IgG by CD64 and CD32a caused the decrease in phagocytosis
(140). Surprisingly, though IVIG dimers and multimers are
not necessary for therapeutic efficacy in murine models for
ITP, small IVIG oligomers provided more potent inhibition
of phagocytosis, indicating a role of IVIG immune complexes
in blocking pathogenic immune complexes from binding to
activating FcγRs (141). Consistent with this observation, immune
complexes formed with the anti-citrullinated protein antibodies
isolated from rheumatoid arthritis patients bound preferentially
to activating and not inhibiting FcγRs expressed on CHO
cells (142). Moreover, CD64 on activated neutrophils and
CD32a on macrophages were recognized as receptors for the
autoantibody immune complex, eliciting the secretion of pro-
inflammatory cytokines. These observations formed the basis
for developing engineered multivalent immune complexes as
therapeutic options.
Considerations Regarding Immune Complex Size in
Therapeutic Development
Multivalent synthetic immune complexes show promise
and may prove useful in the clinic. For example, a trivalent
IgG-Fc construct inhibited autoantibody-mediated FcγR-
dependent cellular responses in primary human cells and
autoimmune murine models (143). Likewise, an engineered
hexameric-Fc construct bound to primary differentiated
human macrophages and triggered internalization, colocalizing
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with the activating FcγRs and elicited a decrease in the
phagocytosis of antiCD20-coated human B cells and platelets
in a murine ITP model (144). The hexameric Fc construct
did not trigger internalization of CD32b and exhibited a
much shorter serum half-life in animal models than IgG1,
however, the inhibition was effective for several days after
the initial injection, suggesting a potential for clinical use.
In contrast to the approach of preventing the internalization
of pathogenic immune complex to block phagocytosis of
healthy cells or activating a pro-inflammatory response, a
designed bispecific antibody formed larger complexes that
neutralized soluble antigens, leading to rapid clearance
from serum of a murine model (145). Thus, studies of
multivalent IgG-FcγR interactions provide guidance for
the development of effective therapeutic options. However,
there are multiple antibody and antigen associated factors
which govern the antigenicity of immune complexes that
must be considered when designing antibodies with defined
FcγR-dependent functions.
Features of the Antibody and Antigen That
Impact Antigenicity of the Immune
Complex in vivo
The Ratio of Antibody to Antigen
Antibody concentration relative to antigen changes throughout
the progression of an immune response against an infectious
pathogen. Considering influenza infection as an example, the B-
cell response can take up to 7–14 days to produce antibodies
(146). Generally, the antigen-specific antibody titers increased
by up to 10.2-fold, depending on the patient, vastly changing
the antibody to antigen ratio and the antibody production
can be sustained or subside depending on clearance of
the organism.
A minimal threshold of antibody density must be surpassed
to elicit an immune response during encounters between
an opsonized target and effector cell, typically seen during
pathogenic infection (147, 148). Antibody concentrations that
exceed the threshold lead to an increase in phagocytic activity,
as demonstrated by primary mouse bone marrow derived
macrophages phagocytosing opsonized sheep erythrocytes.
Moreover, at relatively high concentrations of IgG, a valency
dependent induction of IL-10 production was seen (148).
Similarly, infection with Cryptococcus neoformans in mice could
be cleared using a specific ratio of antibody to antigen, ratios
with excessive antibody led to a detrimental host response mainly
due to a reduction in pro-inflammatory cytokines secretion in
organs associated with the infection (149). Apart from changes
in cytokine secretion potential, larger immune complexes formed
with high concentrations of neutralizing antibody against dengue
virus actually inhibited antibody-dependent enhancement by
binding to the inhibitory receptor CD32b on phagocytic
monocytes (150). Thus, relative antibody concentration can
modulate immune response in an FcγR-dependent manner by
altering the size and concentration of immune complexes; this
effect may be similar to the therapeutic benefit of IVIG in
autoimmune conditions.
Concentration of the Immune Complex
Immune complex concentration likewise impacts viral infection.
Apart from the traditional view of Fab-mediated neutralizing
activity, Fc dependent effector functions are becoming
increasingly recognized in protection against viral infection
(16, 17, 151). Classical FcγR-dependent protective mechanisms
such as ADCC and ADCP, as well as antibody dependent
enhancement of infection, are influenced by the size of the
immune complex and IgG subtype coating the viral particle
(17, 152). The production of a high concentration of immune
complexes are common during chronic viral infection in mice
(153). However, high concentrations do not always lead to
favorable outcomes. A high concentration of immune complex
blocked FcγRs on primary murine macrophages and dendritic
cells, negatively impacting viral clearance, and other FcγR-
related activity (153). These phenomena were independent of
CD32b and reversed once the immune complex concentration
was reduced. Thus, the role of FcγRs during pathogen infection
is complex and varied but there is a clear dependence of cellular
response based on immune complex size and concentration,
similar to that observed in autoimmune disease discussed above.
Affinity of the Antibody for Antigen
At a fixed antibody concentration, the affinity of the antibody
toward the antigen can determine how many Fcs are displayed
on the immune complex and are available to interact with FcγRs
(154). A recent study showed that at saturating concentrations,
antibodies with high affinity for antigen elicited a weaker ADCC
response compared to antibodies with lower affinity (KD =
0.8 nM and 72 nM, respectively) (155). The observed difference
in the immune response was attributed to the higher proportion
of monovalent antigen binding displayed by the lower affinity
antibody, recruiting a larger number of antibodies to the cell
surface and increasing the number of Fcs available to the
leukocyte. A notable feature of this observation is the initial
IgG response often produces antibodies with antigen-binding
affinities similar to the lower affinity antibody in this study.
Antibody concentration and antibody-antigen affinity are not
the only factors affecting immunogenicity of immune complex.
A comparative analysis of three anti-TNFα antibodies with a
range of affinities (KD = 0.18–5.1 nM) showed that the size
and composition of the immune complex was determined by
the properties associated with epitope location and binding
energetics (156).
Epitope and Antigen Location
Location of the epitope influences the immune response.
Neutralizing antibodies targeting the stalk region of the influenza
hemagglutinin protein induced FcγR-dependent cytotoxicity
while antibodies binding the head domain did not (12).
A comparable analysis of anti-Ebola antibodies showed that
binding to the most membrane distal portion of viral surface
glycoprotein elicited the highest ADCP and antibody-dependent
neutrophil phagocytosis (ADNP) compared to antibodies that
bound to the membrane proximal regions (157). Even though
epitope location on the antigen is not directly implicated in
changes in immune complex size in these studies, it is likely
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that the epitope location causes changes in immune complex
properties since three different monoclonal antibodies against
different epitopes on sCD154 and TNFα also formed different
immune complexes (156, 158). In other cases, the height of
the antigen from the target surface affected phagocytosis in a
valency-independent manner (55). Antigens which are <10 nm
from target surface promoted phagocytosis when compared to
antigens further away from the surface because close contact
between target and effector cell surface was necessary to exclude
effector cell the inhibitory CD45 from the immune synapse
following FcγRs clustering (as noted above). Additionally,
antibodies binding West Nile virus epitopes that are normally
buried can form immune complexes, given sufficient incubation
time, though these immune complexes are smaller and led to
lower neutralization levels (154). Thus, location of the epitope
can affect the immune response but the effect of epitope location
on immune complex size is not fully understood.
The location of the antigen (soluble or cell bound) affects
FcγR clustering and the subsequent immune response. A soluble
antigen may form relatively smaller immune complexes which
are endocytosed but a cell surface antigen forms a relatively larger
opsonized target that is more likely phagocytized as determined
using mouse bone marrow-derived macrophages (133). Both
mechanisms, triggered through FcγRs, are distinct and induce
different signaling and subsequent immune responses (128, 159).
In one example, small soluble immune made with soluble CD154
would be expected to be endocytosed, and CD154 tethered to a T
cell membrane led to the formation of very large complexes at the
cell surface (158). Surprisingly, the specific monoclonal antibody
greatly influenced the immune complex structure. It is also
known that opsonized targets can exhibit lateral diffusion on the
leukocyte surface which also affects the multivalent interaction
with FcγRs (160).
Malleable vs. Rigid Target Surfaces
In addition to size and shape, deformability of the target
also impacts activation. The phagocytosis of opsonized
polyacrylamide beads tuned to exhibit different rigidity
established that phagocytosis of ridged particles was preferred
over relatively more deformable particles by mouse bone
marrow-derived macrophages (161). A related study
demonstrated that murine macrophage RAW264.7 cells
phagocytosed emulsion droplets at a lower IgG concentration
when compared to solid particles (162). It was speculated that
the attachment of IgG on the surface of rigid particles prevents
the lateral diffusion of opsonizing antibodies, while lateral
diffusion was observed in opsonized emulsion droplet. Thus,
the location of the antigen, which facilitated higher cell surface
FcγRs interaction at lower antibody concentrations, can affect
recognition of the complex.
IgG-Subclass Impact Immune Response
FcγR binding is also affected by IgG subclass. Specificity of a
specific IgG subclass binding to a FcγR is largely studied in
context of a monovalent interaction (23), however, immune
complexes and opsonized target cells are the natural ligands.
Additionally, specific IgG subclasses are related to various
disorders indicating immune complex composition is important
(1, 152, 163). Therefore, studying these interactions in a
multivalent form is required to accurately determine their
binding properties and the subsequent immune response. The
observation that immune complexes of certain IgG subclasses
only bind at higher concentrations indicates that IgG subclass is
also a variable which can affect the immune response (164).
The Fcs of different IgG subclasses have distinct amino acid
residues and hinge regions which can affect binding to the FcγRs,
despite a high degree of sequence conservation (Figure 2) (1). A
systematic analysis of multivalent binding for the four human
IgG subclasses to the cell surface FcγRs revealed the IgG2 and
IgG4 subclasses, which showed minimal affinity in a monovalent
interaction, bound as immune complexes to FcγRs expressed
on CHO cells at higher concentrations (164). This study also
demonstrated that allotype variants of FcγRs had different
binding properties toward immune complexes generated by
different IgG subtypes. CD16a V158 bound IgG3 immune
complexes with high affinity while CD16a F158 bound more
weakly and CD32a H131 had a higher affinity to IgG2 immune
complex compared to CD32a R131. Another report showed
that the CD32a H131 variant bound to IgG1, IgG2, and IgG3
with higher affinity than CD32a R131. This observation may
explain why the CD32a R131 allotype is associated with greater
susceptibility to bacterial infections and autoimmune disorders
(163). Thus, the wide range of binding affinities displayed by
FcγRs toward IgG subclass specific immune complexes can
impact clinical outcome.
The use of different IgG subclasses in designed immune
complexes can also impact potential therapeutic use. Incubation
of a hexameric IgG1 Fc construct, discussed above as an inhibitor
of phagocytosis, elicited the release of higher cytokine levels in
whole blood when compared to PBMCs, likely due to CD16b
engagement on neutrophils (not present in PBMCs) (165).
Furthermore, the hexameric IgG1 Fc construct also triggered
release of cytokines from platelets through a CD32a-dependent
interaction. However, a hexameric IgG4 Fc construct did not
promote the release of cytokines from neutrophils or platelets.
This result is consistent with the reduced affinity of IgG4 for
CD16b and CD32a when compared with IgG1, highlighting the
potential utility of specific FcγR interactions.
SUMMARY
The multitude of factors influencing the immune system each
affects a wide range of responses. This review covers a relatively
limited collection of variables that contribute to an FcγR-
dependent immune response (Figure 1). There appear to be few
inviolable laws governing this aspect of the immune system, and
every newly discovered variable introduce a new handle to tune
the immune response, at least in vitro. It is well known that
different monoclonal antibodies to a single target elicit different
responses, in many cases through the mechanisms described
here. If any lessons are to be learned, it is that each antibody
must be thoroughly evaluated using systems that recapitulate
as closely as possible endogenous immune system components.
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One striking example of this tenet is the observation that the
efficacy of a hexameric IgG1 Fc increased when neutrophils and
platelets were incorporated in an in-vitro assay with PBMCs
(165). Moreover, soluble complement components can also bind
the immune complex to affect the immune response as reported
in few studies described above (130, 148, 149). Laboratory
studies often focus on immune complexes formed bymonoclonal
antibodies, but that is likely not the case in vivo with a
polyclonal immune response to vaccines or infection; one study
demonstrated that a mixture of disease neutralizing and disease
enhancing antibodies against Bacillus anthracis formed immune
complexes that elicited a protective immune response (166).
Thus, these observations highlight the complex yet important
features associated with studying FcγRs function in vivo.
Animal models have, and will continue to have, an important
role in studies designed to understand human FcγRs in immune
function. Despite the differences in FcγR cellular expression
patterns and minor differences in binding affinities to human
IgG subclass, animal (mainly murine and non-human primate)
models have sufficiently recapitulated human FcγR biology to be
used for studying FcγR function and test therapeutic molecules
(167–173). A recent study determined that the mouse FcγRIV
and the human equivalent to human CD16a both share the
conserved N-glycosylation site at N162 which mediates tight
binding to afucosylated mouse IgG similar to observations in
human system, and human IgG binds mouse FcγRs with similar
affinity patterns as human FcγRs demonstrating conservation
of certain functional features of human FcγR biology in mouse
model (170, 174). Furthermore, several studies mentioned
in this review have employed murine autoimmune models,
humanized models, cell lines or primary cells to test efficacy
of engineered antibody products and delineate mechanistic
aspects of the FcγRs dependent cellular response, demonstrating
that these models are indispensable for understanding human
FcγR biology (61, 66, 139, 141, 143, 162). The two successful
strategies to attain humanized FcγR mouse models eliminate
the influence of mouse FcγRs in studying human FcγR function
in these models and can uncover novel role of FcγRs in
autoimmune disorders, infection and cancer immunity (175,
176). However, important yet undefined FcγR variables including
post-translational modification including glycosylation as well
as copy number variation and interaction with coexpressed
membrane proteins likely vary in animal models. It is
likely that organism diversity in these key variables likewise
differentially impacts immune function, comparable to the
diversity attributed to protein coding regions and gene variability
between species.
It is worth highlighting the role of post translation
modification of the FcγRs as another critical variable that is
overlooked due to the historical inability to resolve differences
in the glycosylation of endogenous material. One future
challenge will be matching the level of detail known regarding
serum IgG glycosylation with studies of functionally-relevant
FcγR modifications as these have the potential to exert an
enormous influence on the immune response. Differential gene
expression profiles of the glycan modifying enzymes are present
in monocytes, dendritic cells, and macrophages, suggesting
the potential for the functionally-relevant differentiation and
maturation specific N-glycosylation modifications (177). A
complete understanding of the immune response will require
the definition of these recently discovered variables, with the
likelihood that more variables will emerge.
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